MEDNAX Inc. [MD] stock is down -3.04 while the S&P 500 has fallen -0.48% on Tuesday, 11/17/20. While at the time of this article, MD ATR is sitting at 1.07, with the beta value at 1.88. This stock’s volatility for the past week remained at 5.39%, while it was 5.71% for the past 30-day period. MD has fallen -$0.6 from the previous closing price of $19.74 on volume of 2.81 million shares.

On 6, November 2020, MEDNAX Reports Third Quarter Results. According to news published on Yahoo Finance, MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in prenatal, neonatal, and pediatric services, today reported a net loss of $41.0 million, or $0.49 per share for the three months ended September 30, 2020, primarily reflecting a non-cash loss on the classification of the MEDNAX Radiology Solutions medical group to assets held for sale. On a non-GAAP basis, MEDNAX reported Adjusted EPS from continuing operations of $0.37.

Analyst Birdseye View:

The most recent analyst activity for MEDNAX Inc. [NYSE:MD] stock was on January 03, 2020, when it was Downgrade with a Neutral rating from Citigroup, which also raised its 12-month price target on the stock to $29. Before that, on October 19, 2020, Deutsche Bank Recapitulated a Sell rating and elevated its amount target to $12. On December 12, 2019, Stifel Upgrade a Buy rating and boosted its price target on this stock from $25 to $33. On September 06, 2019, BofA/Merrill Downgrade an Underperform rating. On January 15, 2019, Citigroup Upgrade a Buy rating. On January 03, 2019, Deutsche Bank Initiated a Hold rating and boosted its amount on this stock to $34. On November 16, 2018, UBS Initiated a Sell rating and boosted its target amount on this stock to $37.

In the past 52 weeks of trading, this stock has oscillated between a low of $7.37 and a peak of $28.66. Right now, according to Wall Street analyst the average 12-month amount target is $19.00. At the most recent market close, shares of MEDNAX Inc. [NYSE:MD] were valued at $19.14. According to the average price forecast, investors can expect a potential return of 0.0%.

FUNDAMENTAL ANALYSIS

MEDNAX Inc. [NYSE:MD] most recently reported quarterly sales of 460.63 billion, which represented growth of -48.20%. This publicly-traded organization’s revenue is $254,512 per employee, while its income is -$83,310 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -22.82, -50.15, 9.75 and -27.52 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 54.85 and the whole liability to whole assets at 43.92. It shows enduring liability to the whole principal at 54.14 and enduring liability to assets at 0.43 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 18.73 points at 1st support level, the second support level is making up to 18.32. But as of 1st resistance point, this stock is sitting at 19.61 and at 20.08 for 2nd resistance point.

MEDNAX Inc. [MD] reported its earnings at $0.37 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $0.4/share signifying the difference of -0.03 and -7.50% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $0.32 calling estimates for $0.09/share with the difference of 0.23 depicting the surprise of 255.60%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for MEDNAX Inc. [NYSE:MD] is 3.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.35. Now if looking for a valuation of this stock’s amount to sales ratio it’s 0.66, it’s amount to book ratio is 1.56 and showing 82.50 of P/E (TTM) ratio.

Insider Stories

The most recent insider trade was by Nikolopoulos Nicholas J, EVP Chf Strategy & Growth Offi, and it was the sale of 10000.0 shares on Sep 15. Andreano Dominic J, the EVP, General Counsel and Secy, completed a sale of 22000.0 shares on Sep 15.